Seems like a bit of interest on the ADO thread today! :)Onshow -...

Seems like a bit of interest on the ADO thread today! :)

Onshow - you brought up a valid point

- Roche would not be able to finalise anything with Anteo until they had PMA approval - therefore nothing could be announced as there is nothing of substance to announce as this is all part of the contract process.

- Once the PMA is approved that then begins a new phase - In my opinion the negotiations would have taken place before the PMA otherwise it would be a waste of time and money for both parties involved.

- In my opinion contracts would be negotiated subject to PMA

- Some thing that hasnt been mentioned today is the choice of tests that have been PMA approved

It would be logical that Roche would want to utilise MixnGo in the test or tests that gives the most groundbreaking results with the use of mixngo

What am I talking about - Look at the link below to the Aus Biotech presentation

Aus Biotech Presentation September 2011 - Go to Slide 9

It is clear that there is 3 familys of tests that provide the most outstanding results

1. IL-6 - 60 times improvement factor

2.PSA - 57 times improvement factor

3. HBsAg - 43 times improvement factor

HBsAg - Hepititis B testing same tests as Roche has just got PMA for!

All I will say to shareholders on Hot Copper is understand the value of the shares you hold - these investment opportunities dont come along all that often

Maybe just maybe the stars are starting to align

Good luck all - Interesting times ahead

Twinvest